Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

Der Aktionär

May 14, 2020

Biotech-Geheimtipp Abivax gibt im Kampf gegen Covid-19 Gas – Aktie explodiert 45%

Scrip

May 14, 2020

Abivax To Launch ‘Triple-Action’ COVID-19 Therapy Trial

BioWorld

May 14, 2020

Abivax to evaluate anti-inflammatory effects of ABX-464 in large-scale COVID-19 trial

Drug Discovery World

May 14, 2020

Abivax’s ABX464 has potential triple action for Covid-19 treatment

Contagion Live

May 14, 2020

COVID-19 Treatment Candidate ABX464 Shows Promise In Vitro

  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • …
  • 46

References available upon request.

© 2025 All rights reserved by Abivax 07/2024 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn